Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100

21 Dec 2022

Abstract excerpt

BOLD-100 (sodium trans-[tetrachlorobis(1H indazole)ruthenate(III)]) is a ruthenium-based anticancer compound currently in clinical development. The identification of cancer types that show increased sensitivity towards BOLD-100 can lead to improved developmental strategies. Sensitivity profiling can also identify mechanisms of action that are pertinent for the bioactivity of complex therapeutics. Sensitivity to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Drug Discovery Methods
Share to Metal complexes synthesis and properties
Share to Molecular Biology Techniques and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36612025
DOI: 10.3390/cancers15010028

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Utilization of Cancer Cell Line Screening to Elucidate the Anticancer Activity and Biological Pathways Related to the Ruthenium-Based Therapeutic BOLD-100PMID 36612025Read ↗

Drug sensitivity in cancer cell lines is not tissue-specificSemantic proximity Read ↗

scDrugAtlas: an integrative single-cell drug response database for dissecting tumor heterogeneity in therapeutic efficacySemantic proximity Read ↗

Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.Semantic proximity Read ↗

A Deep Learning Framework for Prediction of Clinical Drug Response of Cancer Patients and Identification of Drug Sensitivity Biomarkers using Preclinical SamplesSemantic proximity Read ↗

Drug Sensitivity Prediction From Cell Line-Based Pharmacogenomics Data: Guidelines for Developing Machine Learning ModelsSemantic proximity Read ↗

The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose DeprivationSemantic proximity Read ↗

Deep learning-driven drug response prediction and mechanistic insights in cancer genomicsSemantic proximity Read ↗

Heterogeneous therapy-resistant cancer cells have distinct and exploitable drug sensitivity profilesSemantic proximity Read ↗

Systematic identification of genomic markers of drug sensitivity in cancer cellsSemantic proximity Read ↗

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivitySemantic proximity Read ↗

Development of Drug-resistant Cell Lines for Experimental ProceduresSemantic proximity Read ↗

Tissue specificity of <i>in vitro</i> drug sensitivitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.